IRL757

DRUG4 trials

Sponsors

Integrative Research Laboratories Sweden AB, Integrative Research Laboratories AB

Conditions

ApathyNot Applicable as This is a Mass Balance/Pharmacokinetic Study Performed in Healthy SubjectsNot DeterminedPARKINSON DISEASE (Disorder)Parkinson's Disease and ApathySafety

Phase 1

First-In-Human (FIH) Trial Evaluating the Safety and Tolerability of Single and Multiple Ascending Oral Doses of IRL757 in Healthy Volunteers

CompletedNCT06493045

Integrative Research Laboratories ABNot Determined

Start: 2024-05-16End: 2025-02-07Updated: 2026-05-15

Phase I Trial Evaluating the Pharmacokinetics of Single Ascending Oral Doses of IRL757 in Healthy Elderly Volunteers

CompletedNCT06699628

Integrative Research Laboratories ABApathy, Not Applicable as This is a Mass Balance/Pharmacokinetic Study Performed in Healthy Subjects

Start: 2024-09-23End: 2024-11-11Updated: 2026-02-05

A Phase 1b, Prospective, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Tolerability of Multiple Oral Doses of IRL757 in Participants with Parkinson’s Disease and Apathy

RecruitingCTIS2025-523612-37-00

Integrative Research Laboratories Sweden ABParkinson's Disease and Apathy

Start: 2026-01-23Target: 125Updated: 2026-01-14

Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy

RecruitingNCT07461220

Integrative Research Laboratories ABApathy, PARKINSON DISEASE (Disorder), Safety

Start: 2026-02-18End: 2027-05-01Target: 75Updated: 2026-09-03